Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II)

NCT03943342 is registered in ClinicalTrials.gov with Kerry Rogers as lead sponsor.

NCT NCT03943342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03943342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II)
Lead sponsor
Kerry Rogers
Phase
Phase 2
Overall status
Withdrawn
Start date
March 11, 2020
Completion date
July 20, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, loss of chromosome 17p